BioAge Labs Reports Positive Interim Phase 1 Data for BGE-102, Demonstrating Strong hsCRP Reduction
BIOA has more than doubled off its 52-week low of $2.88.
Summary
BioAge Labs announced positive interim Phase 1 data for its novel NLRP3 inhibitor, BGE-102, showing an 86% reduction in hsCRP and a favorable safety profile in patients with elevated cardiovascular risk.
Key Events · Product Development and Regulatory · BIOA
-
Positive Interim Phase 1 Data
BGE-102 achieved an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at Day 14, with 93% of participants reaching normalized levels (<2 mg/L) in obese individuals with elevated cardiovascular risk.
-
Best-in-Class Potential Indicated
The data suggests BGE-102 has the potential for best-in-class hsCRP reduction, along with significant reductions in IL-6 and fibrinogen, key markers of systemic inflammation and cardiovascular risk.
-
Favorable Safety Profile
BGE-102 was well tolerated with a favorable safety profile, showing infrequent, mild to moderate adverse events and no dose-limiting toxicities.
-
Advancement to Phase 2a
The company plans to initiate a Phase 2a proof-of-concept study in patients with obesity and cardiovascular risk factors in 1H 2026, with data readout anticipated in 2H 2026.
Analysis · BIOA · Life Sciences
This announcement is highly significant for BioAge Labs as it provides strong clinical validation for BGE-102, a key pipeline asset. The substantial reduction in hsCRP, a critical inflammatory marker for cardiovascular risk, along with reductions in IL-6 and fibrinogen, suggests a potent and potentially best-in-class therapeutic profile. The favorable safety data further de-risks the program. These positive results pave the way for the planned Phase 2a study, which is a crucial next step in demonstrating efficacy in a larger patient population and could significantly impact the company's valuation and future prospects.
At the time of this filing, BIOA was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $499.1M. The 52-week trading range was $2.88 to $16.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.